 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...132133134135136137138139140141142143144» |
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, motolimod (VTX 2337) / BMS
New P2 trial, Combination therapy, Metastases: Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 17, 2013
P2, N=175, Recruiting, Sponsor: VentiRx Pharmaceuticals Inc.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change: Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer (clinicaltrials.gov) - Apr 15, 2013
P2, N=37, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
N=48 --> 37
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery: S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer (clinicaltrials.gov) - Apr 15, 2013
P2, N=80, Active, not recruiting, Sponsor: Southwest Oncology Group
N=48 --> 37 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Cetuximab Rechallenge Study (clinicaltrials.gov) - Apr 14, 2013
P2, N=35, Recruiting, Sponsor: Chinese University of Hong Kong
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 11, 2013
P=N/A, N=11, Completed, Sponsor: Fox Chase Cancer Center
Recruiting --> Active, not recruiting N=30 --> 11
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 11, 2013
P=N/A, N=11, Completed, Sponsor: Fox Chase Cancer Center
N=30 --> 11 Recruiting --> Completed
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Combination therapy, Metastases: CETMET: Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Apr 10, 2013
P2, N=120, Recruiting, Sponsor: Karolinska University Hospital
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Docetaxel + Cetuximab + Concurrent Re-Irradiation (Intensity - Modulated Radiation Therapy, IMRT) for Patients With Locoregionally Recurrent Head and Neck Cancer (clinicaltrials.gov) - Apr 9, 2013
P2, N=14, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Trial withdrawal, Metastases: Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib (clinicaltrials.gov) - Apr 7, 2013
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, SIR-Spheres (yttrium-90 microspheres) / SIRTeX Medical
Enrollment change, Metastases: Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib (clinicaltrials.gov) - Apr 7, 2013
P1, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=136 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, linsitinib (ASP7487) / Sling Therap
Trial withdrawal, Metastases: Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
N=136 --> 0 Not yet recruiting --> Withdrawn
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, linsitinib (ASP7487) / Sling Therap
Enrollment change, Metastases: Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Apr 3, 2013
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=66 --> 0
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Surgery, Metastases: EXCITE: Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Apr 3, 2013
P1/2, N=80, Active, not recruiting, Sponsor: University College, London
N=66 --> 0 N=40 --> 80
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Surgery, Metastases: EXCITE: Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer (clinicaltrials.gov) - Apr 3, 2013
P1/2, N=80, Active, not recruiting, Sponsor: University College, London
N=40 --> 80 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Pan tumor: An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status (clinicaltrials.gov) - Apr 1, 2013
P1, N=102, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Mar 28, 2013
P=N/A, N=58, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting Completed --> Terminated; study closed prematurely upon PI's departure from VICC
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Mar 28, 2013
P=N/A, N=58, Terminated, Sponsor: Vanderbilt-Ingram Cancer Center
Completed --> Terminated; study closed prematurely upon PI's departure from VICC N=100 --> 58
- Enrollment closed, Combination therapy: Bevacizumab in Multiple Phase I Combinations (clinicaltrials.gov) - Mar 28, 2013
P1, N=354, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=100 --> 58 Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Immunoreactivity to Cetuximab in Cancer Patients (clinicaltrials.gov) - Mar 28, 2013
P=N/A, N=538, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: A Study in Head and Neck Cancer (clinicaltrials.gov) - Mar 25, 2013
P2, N=230, Active, not recruiting, Sponsor: Eli Lilly and Company
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Surgery, Metastases: Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 24, 2013
P2, N=30, Completed, Sponsor: Herbert Hurwitz
Recruiting --> Active, not recruiting N=45 --> 30
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Surgery, Metastases: Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Mar 24, 2013
P2, N=30, Completed, Sponsor: Herbert Hurwitz
N=45 --> 30 Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
Biomarker, New P1/2 trial, Combination therapy, Metastases: PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) - Mar 20, 2013
P1/2, N=30, Recruiting, Sponsor: University of Chicago
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas (clinicaltrials.gov) - Mar 13, 2013
P2, N=51, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tecentriq (atezolizumab) / Roche
New P2/3 trial, PD(L)-1 Biomarker: RTOG 1216: Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer (clinicaltrials.gov) - Mar 12, 2013
P2/3, N=675, Recruiting, Sponsor: Radiation Therapy Oncology Group
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin (clinicaltrials.gov) - Mar 7, 2013
P2, N=16, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting N=25 --> 16
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab (clinicaltrials.gov) - Mar 6, 2013
P2, N=303, Completed, Sponsor: Centre Francois Baclesse
N=25 --> 16 Recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial initiation date, Metastases: METHEP-2: Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases (clinicaltrials.gov) - Mar 4, 2013
P2, N=256, Recruiting, Sponsor: UNICANCER
Recruiting --> Completed Initiation date: Nov 2010 --> Feb 2011
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 4, 2013
P2, N=65, Recruiting, Sponsor: New Mexico Cancer Care Alliance
Initiation date: Nov 2010 --> Feb 2011 N=50 --> 65
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: Erlotinib in Combination With Cetuximab (clinicaltrials.gov) - Mar 4, 2013
P1, N=48, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
N=50 --> 65 Recruiting --> Active, not recruiting
- ||| imgatuzumab (RO5083945) / Centessa
Trial completion: A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov) - Mar 3, 2013
P1, N=62, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial: CELIM2: Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases (clinicaltrials.gov) - Feb 27, 2013
P2, N=256, Recruiting, Sponsor: Technische Universit
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen
New P2 trial, Metastases: PACER: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 27, 2013
P2, N=41, Recruiting, Sponsor: National Cancer Institute, Naples
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Combination therapy, Metastases: Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck (clinicaltrials.gov) - Feb 27, 2013
P1/2, N=28, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| duligotuzumab (MEHD7945A) / Roche
Trial initiation date, Metastases: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - Feb 25, 2013
P2, N=135, Active, not recruiting, Sponsor: Genentech
Recruiting --> Active, not recruiting Initiation date: Jul 2012 --> Oct 2012
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Combination therapy, Metastases: Everest 2: Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (clinicaltrials.gov) - Feb 24, 2013
P2, N=375, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Initiation date: Jul 2012 --> Oct 2012 Suspended --> Recruiting
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer (clinicaltrials.gov) - Feb 21, 2013
P1, N=12, Terminated, Sponsor: Angela Taber MD
Suspended --> Recruiting Recruiting --> Terminated; Determination to stop enrollment made due to funding
- Taltorvic (ridaforolimus) / Takeda, Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer (clinicaltrials.gov) - Feb 21, 2013
P1, N=12, Terminated, Sponsor: Angela Taber MD
Recruiting --> Terminated; Determination to stop enrollment made due to funding N=25 --> 12
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Combination therapy, Metastases: Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Feb 21, 2013
P1/2, N=48, Completed, Sponsor: National Cancer Institute (NCI)
N=25 --> 12 Active, not recruiting --> Completed
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial termination, Metastases: Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study (clinicaltrials.gov) - Feb 19, 2013
P2, N=7, Terminated, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Recruiting --> Terminated; Due to slow accrual
- 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Enrollment change, Metastases: Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study (clinicaltrials.gov) - Feb 19, 2013
P2, N=7, Terminated, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Terminated; Due to slow accrual N=50 --> 7
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment open, Metastases: DREXNECK: Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2013
P2, N=25, Recruiting, Sponsor: Drexel University
N=50 --> 7 Active, not recruiting --> Recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Metastases: Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma (clinicaltrials.gov) - Feb 18, 2013
P2, N=35, Recruiting, Sponsor: University of Miami Sylvester Comprehensive Cancer Center
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: MACRO-2: Safety and Efficacy Study of mFOLFOX-6 Plus Cetuximab for 8 Cycles Followed by mFOLFOX-6 Plus Cetuximab or Single Agent Cetuximab as Maintenance Therapy in Patients With Metastatic Colorectal Cancer and WT KRAS Tumours (clinicaltrials.gov) - Feb 18, 2013
P2, N=192, Active, not recruiting, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion: A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma (clinicaltrials.gov) - Feb 18, 2013
P2, N=50, Completed, Sponsor: Spanish Cooperative Group for Digestive Tumour Therapy (TTD)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, linsitinib (ASP7487) / Sling Therap
Trial initiation date, Metastases: Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov) - Feb 17, 2013
P2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Initiation date: Dec 2012 --> Jun 2013
- Erbitux (cetuximab) / Eli Lilly, Zelboraf (vemurafenib) / Roche
Enrollment open, Combination therapy, Surgery, Metastases: Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (clinicaltrials.gov) - Feb 14, 2013
P1, N=77, Recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Dec 2012 --> Jun 2013 Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial termination, Metastases: Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC (clinicaltrials.gov) - Feb 11, 2013
P2, N=68, Terminated, Sponsor: Hellenic Oncology Research Group
Not yet recruiting --> Recruiting Withdrawn --> Terminated; Due to poor accrual
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC (clinicaltrials.gov) - Feb 11, 2013
P2, N=68, Terminated, Sponsor: Hellenic Oncology Research Group
Withdrawn --> Terminated; Due to poor accrual N=100 --> 68
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer (clinicaltrials.gov) - Feb 11, 2013
P2, N=16, Terminated, Sponsor: Hellenic Oncology Research Group
N=100 --> 68 N=50 --> 16